Tofacitinib (CP-690550) | ≥99%(HPLC) | Selleck | JAK inhibitor
Pfizer's JAK inhibitor hits the mark in another phase 3 eczema trial | Fierce Biotech
Xeljanz XR (tofacitinib citrate) Modified Release Tablets For the Treatment of Rheumatoid Arthritis - Clinical Trials Arena
Trial Data Confirm Heightened Risks With JAK Inhibitor | MedPage Today
Janus kinase 3 inhibitor - Wikipedia
US, Europe review safety of JAK inhibitors. What about Korea? < Policy < Article - KBR
Pfizer's JAK inhibitor sails through phase 3 in rheumatoid arthritis | Nature Biotechnology
Selective Janus kinase inhibitors come of age | Nature Reviews Rheumatology
Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach | Nature Reviews Rheumatology
Ritlecitinib (PF-06651600) | ≥99%(HPLC) | Selleck | JAK inhibitor
Frontiers | Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review
Inhaled Janus Kinase (JAK) inhibitors for the treatment of asthma - ScienceDirect
JAK Inhibitor Misses Endpoint in Safety Study. Now What? | MedPage Today
Topical JAKs to differentiate the atopic dermatitis pipeline
Janus kinase 3 inhibitor - Wikipedia
Pfizer Strikes JAK Inhibitor Deal Worth Up to $250 Million With Theravance | BioSpace
After 25 years of drug development, do we know JAK? | RMD Open
Pfizer takes risk in pursuing more JAK inhibitor approvals - Pharmaceutical Technology
FDA approves JAK inhibitors as 2nd-line systemic therapy in atopic dermatitis < Pharma < Article - KBR
Pfizer's JAK Inhibitor Xeljanz Racks Up Another FDA Win – PharmaLive
Pfizer and Lilly's JAK inhibitor safety concerns prompt Europe to scrutinize drug class | Fierce Pharma
